Juvenescence Acquires AI Drug-Discovery Company Ro5

Five Arrows Acquires Majority Stake in Juvare LLC

July 28, 2020

Cloud & SaaS

Five Arrows (the corporate private equity arm of Rothschild & Co) has completed a majority investment in Juvare LLC, the provider of emergency preparedness and critical incident management software, purchasing the stake from Thomas H. Lee Partners. Terms were not disclosed; Five Arrows is organizing the investment through its European fund (Five Arrows Principal Investments) and its US fund (Five Arrows Capital Partners) to support Juvare's growth in the US and internationally.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

Jiddu Inc Acquires Nirveda Cognition from CerraCap Ventures

August 13, 2021

AI & Machine Learning

Jiddu Inc (parent of AgShift) has acquired Nirveda Cognition, an enterprise AI document-intelligence platform, in an all-stock transaction announced by investor CerraCap Ventures. The deal brings Nirveda’s AI/document-intelligence capabilities into Jiddu’s ecosystem to expand AgShift’s product capabilities and accelerate AI-driven solutions for food-quality inspection and other enterprise document‑intensive processes.

Novartis Acquires Vedere Bio

September 30, 2020

Biotechnology

Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.